Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Dosing Begins for Phase 3 LIGHTHOUSE Study of BIIB122

Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up…

Turning Words Into Actions May Improve Memory

Acting out a word or phrase may help people keep memory of it — a phenomenon called the enactment effect — and this also may hold true for those with poor motor control due to Parkinson’s disease, according to a review study. “Our meta-analysis found that even Parkinson’s disease…

Dosing Begins in Phase 2a Trial of Oral Treatment to Aid Cognition

Patient dosing has begun in a Phase 2a clinical trial testing oral CST-2032 in combination with CST-107 as a potential way to ease the symptoms of mild cognitive impairment and mild dementia due to Parkinson’s or Alzheimer’s disease, the company developing these therapies, CuraSen Therapeutics, announced. The trial (…

Genetic Mutations May Affect Parkinson’s Progression

Certain genetic mutations may help determine the length of survival in Parkinson’s disease patients, according to findings by a team of researchers from four institutes in Paris. Patients with Parkinson’s who carried a mutation in either the LRRK2 or the PRKN genes were found to live longer than those…